{"id":60151,"date":"2026-03-20T13:38:46","date_gmt":"2026-03-20T05:38:46","guid":{"rendered":"https:\/\/flcube.com\/?p=60151"},"modified":"2026-03-20T13:38:46","modified_gmt":"2026-03-20T05:38:46","slug":"alphamab-oncology-doses-first-patient-in-jskn016-phase-iii-her3-trop2-adc-targets-heavily-pretreated-triple-negative-breast-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=60151","title":{"rendered":"Alphamab Oncology Doses First Patient in JSKN016 Phase III \u2013 HER3\/TROP2 ADC Targets Heavily Pretreated Triple Negative Breast Cancer"},"content":{"rendered":"\n<p><strong>Alphamab Oncology<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/9966:HKG\">HKG: 9966<\/a>) announced <strong>first patient dosing<\/strong> in a <strong>Phase III clinical study<\/strong> for <strong>JSKN016<\/strong>, a <strong>bispecific antibody\u2011drug conjugate (ADC)<\/strong> targeting <strong>HER3 and TROP2<\/strong>, marking advancement to pivotal trials for the novel dual\u2011target therapy in <strong>triple negative breast cancer (TNBC)<\/strong> \u2013 a high\u2011unmet\u2011need indication with limited effective options after multiple prior therapies.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-milestone\">Clinical Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Study<\/strong><\/td><td>Phase III (open\u2011label, randomized, controlled, multicenter)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>JSKN016 \u2013 HER3\/TROP2 bispecific ADC<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Triple negative breast cancer (TNBC)<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Unresectable, locally advanced, recurrent, or metastatic TNBC; <strong>\u22652 prior lines of systemic therapy<\/strong><\/td><\/tr><tr><td><strong>Sites<\/strong><\/td><td><strong>~60 clinical research centers<\/strong> across China<\/td><\/tr><tr><td><strong>First Patient Dosed<\/strong><\/td><td>March 2026<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Alphamab Oncology (HKG: 9966)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-study-design-amp-endpoints\">Study Design &amp; Endpoints<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint Category<\/th><th>Specific Measures<\/th><th>Strategic Significance<\/th><\/tr><\/thead><tbody><tr><td><strong>Primary Endpoints<\/strong><\/td><td><strong>Progression\u2011free survival (PFS)<\/strong> + <strong>Overall survival (OS)<\/strong><\/td><td>Regulatory gold standard for TNBC approval; overall survival critical for differentiation in heavily pretreated setting<\/td><\/tr><tr><td><strong>Secondary Endpoints<\/strong><\/td><td>Investigator\u2011assessed PFS, <strong>ORR<\/strong>, <strong>DCR<\/strong>, <strong>DoR<\/strong><\/td><td>Comprehensive efficacy characterization; ORR supports accelerated approval pathway consideration<\/td><\/tr><tr><td><strong>Comparator<\/strong><\/td><td>Investigator\u2011selected treatment options<\/td><td>Real\u2011world standard\u2011of\u2011care control (chemotherapy, sacituzumab govitecan, or other agents)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-profile-amp-mechanism\">Product Profile &amp; Mechanism<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> <strong>JSKN016<\/strong> \u2013 <strong>bispecific ADC<\/strong> targeting <strong>HER3<\/strong> and <strong>TROP2<\/strong><\/li>\n\n\n\n<li><strong>Technology Platform:<\/strong> Alphamab&#8217;s proprietary ADC and bispecific antibody capabilities<\/li>\n\n\n\n<li><strong>Dual\u2011Target Rationale:<\/strong><\/li>\n\n\n\n<li><strong>TROP2<\/strong> \u2013 highly expressed in TNBC (~90% of cases); validated by sacituzumab govitecan (Trodelvy) approval<\/li>\n\n\n\n<li><strong>HER3<\/strong> \u2013 implicated in resistance mechanisms; co\u2011targeting may overcome single\u2011target ADC resistance<\/li>\n\n\n\n<li><strong>Synergistic payload delivery<\/strong> \u2013 enhanced tumor cell killing through dual receptor engagement<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-strategic-positioning\">Market Context &amp; Strategic Positioning<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Dimension<\/th><th>TNBC Landscape<\/th><th>JSKN016 Position<\/th><\/tr><\/thead><tbody><tr><td><strong>Standard of Care (2L+)<\/strong><\/td><td>Sacituzumab govitecan (Trodelvy) \u2013 TROP2 ADC; chemotherapy<\/td><td>HER3 co\u2011targeting may address Trodelvy resistance; bispecific differentiation<\/td><\/tr><tr><td><strong>Unmet Need<\/strong><\/td><td>Median OS &lt;12 months after 2L progression; limited durable responses<\/td><td>Potential for improved PFS\/OS through dual\u2011mechanism payload delivery<\/td><\/tr><tr><td><strong>Competitive Pipeline<\/strong><\/td><td>Multiple TROP2 ADCs (datopotamab deruxtecan, SKB264); limited HER3\/TROP2 bispecifics<\/td><td>First\u2011to\u2011market potential for dual\u2011target ADC in TNBC if Phase III successful<\/td><\/tr><tr><td><strong>China Market Dynamics<\/strong><\/td><td>TNBC ~15\u201120% of breast cancer cases (~40,000 new cases annually); high unmet need in late\u2011line setting<\/td><td>Domestic development advantage; potential for China\u2011first approval ahead of global markets<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>ADC Market Trajectory:<\/strong> Global ADC market projected to exceed <strong>US$30 billion by 2030<\/strong>; TNBC represents largest solid tumor ADC opportunity beyond HER2+ breast cancer; bispecific ADCs emerging as next\u2011generation modality to overcome resistance.<\/li>\n\n\n\n<li><strong>Alphamab Pipeline Validation:<\/strong> JSKN016 joins JSKN003 (HER2 ADC, Phase III), JSKN033 (PD\u2011L1\/HER2 bispecific ADC, Phase II) in Alphamab&#8217;s ADC franchise; HER3\/TROP2 combination validates platform versatility for novel target pairings.<\/li>\n\n\n\n<li><strong>Clinical Development Risk\/Reward:<\/strong> Phase III in <strong>heavily pretreated (\u22652L) population<\/strong> reflects confidence from earlier\u2011phase data; primary OS endpoint requires <strong>3\u20114 year follow\u2011up<\/strong> for mature data; potential for interim PFS analysis supporting accelerated approval H2 2028\u20112029.<\/li>\n\n\n\n<li><strong>Commercial Partnership Optionality:<\/strong> Alphamab has historically out\u2011licensed China\/commercial rights (JSKN003 to Summit Therapeutics); JSKN016 Phase III execution may attract global partnership interest upon positive interim data; estimated deal value <strong>US$500 million\u20111 billion<\/strong> for ex\u2011China rights.<\/li>\n\n\n\n<li><strong>Manufacturing Considerations:<\/strong> Bispecific ADC production complexity higher than monoclonal ADCs; Alphamab&#8217;s Suzhou manufacturing facility supports clinical supply; commercial scale\u2011up partnership likely required for global launch.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development timelines, efficacy expectations, and partnership potential for JSKN016. Actual results may differ due to risks including safety findings in Phase III, competitive dynamics with approved and investigational TNBC therapies, and manufacturing scale\u2011up challenges.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026032000214_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026032000214_c.\"><\/object><a id=\"wp-block-file--media-e66acbb7-7fcc-4939-98b5-678e48688331\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026032000214_c.pdf\">2026032000214_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026032000214_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-e66acbb7-7fcc-4939-98b5-678e48688331\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Alphamab Oncology (HKG: 9966) announced first patient dosing in a Phase III clinical study for&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,187,62],"class_list":["post-60151","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-adc-xdc","tag-alphamab-oncology","tag-clinical-trial-approval-initiation"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Alphamab Oncology Doses First Patient in JSKN016 Phase III \u2013 HER3\/TROP2 ADC Targets Heavily Pretreated Triple Negative Breast Cancer - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Alphamab Oncology (HKG: 9966) announced first patient dosing in a Phase III clinical study for JSKN016, a bispecific antibody\u2011drug conjugate (ADC) targeting HER3 and TROP2, marking advancement to pivotal trials for the novel dual\u2011target therapy in triple negative breast cancer (TNBC) \u2013 a high\u2011unmet\u2011need indication with limited effective options after multiple prior therapies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=60151\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alphamab Oncology Doses First Patient in JSKN016 Phase III \u2013 HER3\/TROP2 ADC Targets Heavily Pretreated Triple Negative Breast Cancer\" \/>\n<meta property=\"og:description\" content=\"Alphamab Oncology (HKG: 9966) announced first patient dosing in a Phase III clinical study for JSKN016, a bispecific antibody\u2011drug conjugate (ADC) targeting HER3 and TROP2, marking advancement to pivotal trials for the novel dual\u2011target therapy in triple negative breast cancer (TNBC) \u2013 a high\u2011unmet\u2011need indication with limited effective options after multiple prior therapies.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=60151\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-20T05:38:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60151#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60151\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Alphamab Oncology Doses First Patient in JSKN016 Phase III \u2013 HER3\\\/TROP2 ADC Targets Heavily Pretreated Triple Negative Breast Cancer\",\"datePublished\":\"2026-03-20T05:38:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60151\"},\"wordCount\":586,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"Alphamab Oncology\",\"Clinical trial approval \\\/ initiation\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=60151#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60151\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=60151\",\"name\":\"Alphamab Oncology Doses First Patient in JSKN016 Phase III \u2013 HER3\\\/TROP2 ADC Targets Heavily Pretreated Triple Negative Breast Cancer - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-20T05:38:46+00:00\",\"description\":\"Alphamab Oncology (HKG: 9966) announced first patient dosing in a Phase III clinical study for JSKN016, a bispecific antibody\u2011drug conjugate (ADC) targeting HER3 and TROP2, marking advancement to pivotal trials for the novel dual\u2011target therapy in triple negative breast cancer (TNBC) \u2013 a high\u2011unmet\u2011need indication with limited effective options after multiple prior therapies.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60151#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=60151\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60151#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alphamab Oncology Doses First Patient in JSKN016 Phase III \u2013 HER3\\\/TROP2 ADC Targets Heavily Pretreated Triple Negative Breast Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Alphamab Oncology Doses First Patient in JSKN016 Phase III \u2013 HER3\/TROP2 ADC Targets Heavily Pretreated Triple Negative Breast Cancer - Insight, China&#039;s Pharmaceutical Industry","description":"Alphamab Oncology (HKG: 9966) announced first patient dosing in a Phase III clinical study for JSKN016, a bispecific antibody\u2011drug conjugate (ADC) targeting HER3 and TROP2, marking advancement to pivotal trials for the novel dual\u2011target therapy in triple negative breast cancer (TNBC) \u2013 a high\u2011unmet\u2011need indication with limited effective options after multiple prior therapies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=60151","og_locale":"en_US","og_type":"article","og_title":"Alphamab Oncology Doses First Patient in JSKN016 Phase III \u2013 HER3\/TROP2 ADC Targets Heavily Pretreated Triple Negative Breast Cancer","og_description":"Alphamab Oncology (HKG: 9966) announced first patient dosing in a Phase III clinical study for JSKN016, a bispecific antibody\u2011drug conjugate (ADC) targeting HER3 and TROP2, marking advancement to pivotal trials for the novel dual\u2011target therapy in triple negative breast cancer (TNBC) \u2013 a high\u2011unmet\u2011need indication with limited effective options after multiple prior therapies.","og_url":"https:\/\/flcube.com\/?p=60151","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-20T05:38:46+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=60151#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=60151"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Alphamab Oncology Doses First Patient in JSKN016 Phase III \u2013 HER3\/TROP2 ADC Targets Heavily Pretreated Triple Negative Breast Cancer","datePublished":"2026-03-20T05:38:46+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=60151"},"wordCount":586,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","Alphamab Oncology","Clinical trial approval \/ initiation"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=60151#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=60151","url":"https:\/\/flcube.com\/?p=60151","name":"Alphamab Oncology Doses First Patient in JSKN016 Phase III \u2013 HER3\/TROP2 ADC Targets Heavily Pretreated Triple Negative Breast Cancer - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-20T05:38:46+00:00","description":"Alphamab Oncology (HKG: 9966) announced first patient dosing in a Phase III clinical study for JSKN016, a bispecific antibody\u2011drug conjugate (ADC) targeting HER3 and TROP2, marking advancement to pivotal trials for the novel dual\u2011target therapy in triple negative breast cancer (TNBC) \u2013 a high\u2011unmet\u2011need indication with limited effective options after multiple prior therapies.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=60151#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=60151"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=60151#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Alphamab Oncology Doses First Patient in JSKN016 Phase III \u2013 HER3\/TROP2 ADC Targets Heavily Pretreated Triple Negative Breast Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/60151","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=60151"}],"version-history":[{"count":2,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/60151\/revisions"}],"predecessor-version":[{"id":60154,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/60151\/revisions\/60154"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=60151"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=60151"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=60151"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}